Drugs / GBR 1302
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02829372 | May 2016 → May 2019 | carcinoma | Ichnos Sciences SA | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-12-17 | Glenmark Pharmaceuticals Ltd. India | Results Glenmark Pharmaceuticals Announces New Data on GBR 1302, a HER2xCD3 Bispecific Antibody, Presented at the ESMO Immuno-Oncology Congress 2018 glenmarkpharma.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-12-17 | Glenmark Pharmaceuticals Ltd. India | Glenmark Pharmaceuticals Announces New Data on GBR 1302, a HER2xCD3 Bispecific Antibody, Presented at the ESMO Immuno-Oncology Congress 2018 glenmarkpharma.com ↗ |
| 2018-08-06 | Glenmark Pharmaceuticals Ltd. India | Glenmark Pharmaceuticals and Harbour BioMed Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers glenmarkpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GBR 1302 | “Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers” NCT02829372 ↗ |
| Route | Intravenous | “Increasing doses, IV on day 1 and 15 of each 28 day cycle” NCT02829372 ↗ |